1887

Journal of General Virology header logo

Volume 85, Issue 8

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen Free

Abstract

The immunogenicity and protective efficacy of a DNA and recombinant modified vaccinia Ankara (MVA) vaccine administered by two different routes were investigated. DNA expressing HIV-1 IIIB , , , , and , and MVA expressing HIV-1 IIIB , and and simian immunodeficiency virus (SIV) macJ5 / and vaccinia HIV-1 , were used as immunogens. Four cynomolgus macaques received DNA intramuscularly (i.m.) at month 0 and intrarectally (i.r.) and intra-orally (i.o.) at 2 months, followed by MVA i.m. at 4 months and i.r. and i.o. at 8 months. Another group of four monkeys received the same immunogens but only i.m.. Overall, stronger cellular immune responses measured by ELISPOT and T-cell proliferation assay were detected in the group primed i.m. and boosted mucosally. Following homologous intravenous simian-human immunodeficiency virus (SHIV) challenge, one of eight vaccinated animals was completely protected. This monkey, immunized i.m. and i.r.+i.o., exhibited the highest levels of HIV Env, Nef and Tat antibodies, high HIV Tat cytotoxic T-lymphocyte activity and T-lymphocyte proliferative responses to HIV Env. Four weeks post-challenge none of the monkeys immunized i.m. and i.r.+i.o., and only two out of four animals immunized i.m., demonstrated detectable plasma viral RNA levels. In contrast, all eight control animals had demonstrable plasma viral RNA levels 4 weeks post-challenge. Thus, stronger cellular immune responses and reduction of challenge virus burden were demonstrated in animals immunized i.m. as well as mucosally, compared with animals immunized i.m. only. The breadth and magnitude of the induced immune responses correlated with protective efficacy.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79869-0
2004-08-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/8/vir852407.html?itemId=/content/journal/jgv/10.1099/vir.0.79869-0&mimeType=html&fmt=ahah

References

  1. Allen T. M., Mortara L., Mothe B. R. 14 other authors 2002; Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 76:4108–4112 [CrossRef]
     [Google Scholar]
  2. Amara R. R., Villinger F., Altman J. D. 19 other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74 [CrossRef]
     [Google Scholar]
  3. Amara R. R., Villinger F., Staprans S. I. 10 other authors 2002; Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 76:7625–7631 [CrossRef]
     [Google Scholar]
  4. Baba T. W., Liska V., Hofmann-Lehmann R. 16 other authors 2000; Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6:200–206 [CrossRef]
     [Google Scholar]
  5. Barouch D. H., Kunstman J., Kuroda M. J. 11 other authors 2002; Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335–339 [CrossRef]
     [Google Scholar]
  6. Barouch D. H., Kunstman J., Glowczwskie J. 12 other authors 2003; Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 77:7367–7375 [CrossRef]
     [Google Scholar]
  7. Belyakov I. M., Hel Z., Kelsall B. 13 other authors 2001; Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 7:1320–1326 [CrossRef]
     [Google Scholar]
  8. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., Liljeström P. 1997; Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retrovir 13:1487–1495 [CrossRef]
     [Google Scholar]
  9. Biberfeld G., Thorstensson R., Bergstrom M., Naucler A., Costa C. M. 1988; Enzyme immunoassays for the demonstration of antibodies to HIV-2SBL-6669 and HTLV-IV (SIVmac. AIDS 2:195–199 [CrossRef]
     [Google Scholar]
  10. Blanchard T. J., Alcami A., Andrea P., Smith G. L. 1998; Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79:1159–1167
     [Google Scholar]
  11. Borrow P., Lewicki H., Wei X. 8 other authors 1997; Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205–211 [CrossRef]
     [Google Scholar]
  12. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. 1985; A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521–530 [CrossRef]
     [Google Scholar]
  13. Cafaro A., Titti F., Fracasso C. 19 other authors 2001; Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P. Vaccine 19:2862–2877 [CrossRef]
     [Google Scholar]
  14. Calarota S. A., Kjerrstrom A., Islam K. B., Wahren B. 2001; Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther 12:1623–1637 [CrossRef]
     [Google Scholar]
  15. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. 1998; Highly attenuated modified vaccinia virus Ankara (MVA) replicates in baby hamster kidney cells (BHK), a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79:347–352
     [Google Scholar]
  16. Drexler I., Antunes E., Schmitz M., Wolfel T., Huber C., Erfle V., Rieber P., Theobald M., Sutter G. 1999; Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen-A*0201-restricted cytotoxic T cells in vitro and in vivo . Cancer Res 59:4955–4963
     [Google Scholar]
  17. Gilljam G. 1993; Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res Hum Retrovir 9:431–438 [CrossRef]
     [Google Scholar]
  18. Gruters R. A., van Baalen C. A., Osterhaus A. D. 2002; The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20:2011–2015 [CrossRef]
     [Google Scholar]
  19. Hanke T., McMichael A. J. 2000; Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951–955 [CrossRef]
     [Google Scholar]
  20. Hanke T., McMichael A. J., Mwau M., Wee E. G., Ceberej I., Patel S., Sutton J., Tomlinson M., Samuel R. V. 2002; Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 20:1995–1998 [CrossRef]
     [Google Scholar]
  21. Heeney J. L. 2002; The critical role of CD4+ T-cell help in immunity to HIV. Vaccine 20:1961–1963 [CrossRef]
     [Google Scholar]
  22. Hel Z., Nasca J., Tryniszweska E. 7 other authors 2002; Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169:4778–4787 [CrossRef]
     [Google Scholar]
  23. Hinkula J., Lundholm P., Wahren B. 1997; Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 15:874–878 [CrossRef]
     [Google Scholar]
  24. Isaguliants M. G., Pokrovskaya K., Kashuba V. I., Pokholok D., Hinkula J., Wahren B., Kochetkov S. N. 1999; Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. FEBS Lett 447:232–236 [CrossRef]
     [Google Scholar]
  25. Jin X., Bauer D. E., Tuttleton S. E. 11 other authors 1999; Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991–998 [CrossRef]
     [Google Scholar]
  26. Kjerrstrom A., Hinkula J., Engstrom G., Ovod V., Krohn K., Benthin R., Wahren B. 2001; Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284:46–61 [CrossRef]
     [Google Scholar]
  27. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. 1994; Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650–4655
     [Google Scholar]
  28. Kuroda M. J., Schmitz J. E., Charini W. A., Nickerson C. E., Lifton M. A., Lord C. I., Forman M. A., Letvin N. L. 1999; Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 162:5127–5133
     [Google Scholar]
  29. Lifson J. D., Nowak M. A., Goldstein S. 10 other authors 1997; The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 71:9508–9514
     [Google Scholar]
  30. Lindback S., Karlsson A. C., Mittler J., Blaxhult A., Carlsson M., Briheim G., Sonnerborg A., Gaines H. 2000; Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 14:2283–2291 [CrossRef]
     [Google Scholar]
  31. Liu M. A. 2003; DNA vaccines: a review. J Int Med 253:402–410 [CrossRef]
     [Google Scholar]
  32. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. 2002; Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302:44–57 [CrossRef]
     [Google Scholar]
  33. Lundholm P., Asakura Y., Hinkula J., Lucht E., Wahren B. 1999; Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17:2036–2042 [CrossRef]
     [Google Scholar]
  34. Lundholm P., Leandersson A. C., Christensson B., Bratt G., Sandstrom E., Wahren B. 2002; DNA mucosal HIV vaccine in humans. Virus Res 82:141–145
     [Google Scholar]
  35. Makitalo B., Andersson M., Arestrom I., Karlen K., Villinger F., Ansari A., Paulie S., Thorstensson R., Ahlborg N. 2002; ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques. J Immunol Methods 270:85–97 [CrossRef]
     [Google Scholar]
  36. Mascola J. R., Lewis M. G., Stiegler G. 11 other authors 1999; Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009–4018
     [Google Scholar]
  37. Mascola J. R., Stiegler G., VanCott T. C. 8 other authors 2000; Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210 [CrossRef]
     [Google Scholar]
  38. Mascola J. R., Lewis M. G., VanCott T. C. 15 other authors 2003; Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol 77:10348–10356 [CrossRef]
     [Google Scholar]
  39. Matano T., Shibata R., Siemon C., Connors M., Lane H. C., Martin M. A. 1998; Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72:164–169
     [Google Scholar]
  40. Mayr A., Danner K. 1978; Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41:225–234
     [Google Scholar]
  41. Mellors J. W., Rinaldo C. R. Jr, Gupta P., White R. M., Todd J. A., Kingsley L. A. 1996; Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–1170 [CrossRef]
     [Google Scholar]
  42. Mooij P., Heeney J. L. 2001; Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20:304–321 [CrossRef]
     [Google Scholar]
  43. Nilsson C., Thorstensson R., Gilljam G. 7 other authors 1995; Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp125. Vaccine Res 4:165–175
     [Google Scholar]
  44. Nilsson C., Makitalo B., Berglund P. 8 other authors 2001; Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19:3526–3536 [CrossRef]
     [Google Scholar]
  45. Okuda K., Bukawa H., Hamajima K. 7 other authors 1995; Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retrovir 11:933–943 [CrossRef]
     [Google Scholar]
  46. O'Neill E., Martinez I., Villinger F. 11 other authors 2002; Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol 31:217–227 [CrossRef]
     [Google Scholar]
  47. Osterhaus A. D., van Baalen C. A., Gruters R. A. 9 other authors 1999; Vaccination with Rev and Tat against AIDS. Vaccine 17:2713–2714 [CrossRef]
     [Google Scholar]
  48. Putkonen P., Quesada-Rolander M., Leandersson A. C., Schwartz S., Thorstensson R., Okuda K., Wahren B., Hinkula J. 1998; Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 250:293–301 [CrossRef]
     [Google Scholar]
  49. Quesada-Rolander M., Makitalo B., Thorstensson R., Zhang Y. J., Castanos-Velez E., Biberfeld G., Putkonen P. 1996; Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retrovir 12:993–999 [CrossRef]
     [Google Scholar]
  50. Rogers W. O., Baird J. K., Kumar A. 8 other authors 2001; Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 69:5565–5572 [CrossRef]
     [Google Scholar]
  51. Rosenberg E. S., Billingsley J. M., Caliendo A. M., Boswell S. L., Sax P. E., Kalams S. A., Walker B. D. 1997; Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447–1450 [CrossRef]
     [Google Scholar]
  52. Rosenberg E. S., Altfeld M., Poon S. H. 7 other authors 2000; Immune control of HIV-1 after early treatment of acute infection. Nature 407:523–526 [CrossRef]
     [Google Scholar]
  53. Rud E. W., Cranage M., Yon J., Quirk J., Ogilvie L., Cook N., Webster S., Dennis M., Clarke B. E. 1994; Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 75:529–543 [CrossRef]
     [Google Scholar]
  54. Schmitz J. E., Kuroda M. J., Santra S. 13 other authors 1999; Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857–860 [CrossRef]
     [Google Scholar]
  55. Stittelaar K. J., Kuiken T., de Swart R. L. 8 other authors; 2001; Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700–3709 [CrossRef]
     [Google Scholar]
  56. Sykes K. F., Lewis M. G., Squires B., Johnston S. A. 2002; Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine 20:2382–2395 [CrossRef]
     [Google Scholar]
  57. ten Haaft P., Verstrepen B., Uberla K., Rosenwirth B., Heeney J. 1998; A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72:10281–10285
     [Google Scholar]
  58. van Baalen C. A., Pontesilli O., Huisman R. C., Geretti A. M., Klein M. R., de Wolf F., Miedema F., Gruters R. A., Osterhaus A. D. 1997; Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78:1913–1918
     [Google Scholar]
  59. Verrier B., Le Grand R., Ataman-Onal Y. 8 other authors 2002; Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 21:653–658 [CrossRef]
     [Google Scholar]
  60. Walther-Jallow L., Andersson S., da Silva Z., Biberfeld G. 1999; High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retrovir 15:957–962 [CrossRef]
     [Google Scholar]
  61. Wang R., Epstein J., Baraceros F. M. 14 other authors 2001; Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 98:10817–10822 [CrossRef]
     [Google Scholar]
  62. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P. R., Hu S. L., Haigwood N. L. 1997; Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 71:284–290
     [Google Scholar]
  63. Wee E. G., Patel S., McMichael A. J., Hanke T. 2002; A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83:75–80
     [Google Scholar]
  64. Weiss W. R., Ishii K. J., Hedstrom R. C., Sedegah M., Ichino M., Barnhart K., Klinman D. M., Hoffman S. L. 1998; A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 161:2325–2332
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79869-0
Loading
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
J. Gen. Virol. 85, 2407 (2004); https://doi.org/10.1099/vir.0.79869-0
/content/journal/jgv/10.1099/vir.0.79869-0
/content/journal/jgv/10.1099/vir.0.79869-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error